Assenagon Asset Management S.A. Has $115,000 Holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Assenagon Asset Management S.A. reduced its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 69.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 12,526 shares of the medical technology company's stock after selling 27,960 shares during the quarter. Assenagon Asset Management S.A.'s holdings in Alphatec were worth $115,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. State Street Corp lifted its holdings in shares of Alphatec by 10.1% during the third quarter. State Street Corp now owns 3,138,960 shares of the medical technology company's stock worth $17,453,000 after buying an additional 287,350 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in Alphatec by 11.3% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company's stock valued at $16,280,000 after purchasing an additional 297,850 shares during the last quarter. Royce & Associates LP raised its stake in Alphatec by 15.9% during the 3rd quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company's stock valued at $6,740,000 after purchasing an additional 165,954 shares during the last quarter. Marshall Wace LLP grew its position in Alphatec by 44.7% in the 2nd quarter. Marshall Wace LLP now owns 1,099,692 shares of the medical technology company's stock worth $11,492,000 after purchasing an additional 339,832 shares during the last quarter. Finally, Walleye Capital LLC increased its holdings in shares of Alphatec by 3.2% during the 3rd quarter. Walleye Capital LLC now owns 1,061,462 shares of the medical technology company's stock worth $5,902,000 after purchasing an additional 32,529 shares during the period. 66.35% of the stock is currently owned by institutional investors.

Alphatec Stock Performance

Alphatec stock traded down $0.66 during mid-day trading on Friday, hitting $11.01. 1,741,455 shares of the company were exchanged, compared to its average volume of 1,397,262. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $17.34. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The business has a fifty day moving average of $9.92 and a 200 day moving average of $8.08.

Insider Activity at Alphatec

In related news, CEO Patrick Miles sold 6,687 shares of the company's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $12.00, for a total transaction of $80,244.00. Following the transaction, the chief executive officer now owns 5,501,715 shares in the company, valued at $66,020,580. This represents a 0.12 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP David Sponsel sold 58,283 shares of the firm's stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $10.71, for a total transaction of $624,210.93. Following the completion of the sale, the executive vice president now owns 502,311 shares of the company's stock, valued at $5,379,750.81. The trade was a 10.40 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 65,208 shares of company stock valued at $706,835 in the last ninety days. Insiders own 22.80% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ATEC shares. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Alphatec in a research note on Tuesday, January 14th. Needham & Company LLC raised their price objective on Alphatec from $13.00 to $16.00 and gave the stock a "buy" rating in a research report on Monday, January 13th. Finally, Barclays lifted their price objective on Alphatec from $20.00 to $21.00 and gave the stock an "overweight" rating in a report on Wednesday. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Alphatec presently has an average rating of "Moderate Buy" and a consensus target price of $17.56.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.